SCYNEXIS INC (SCYX) - Dilution Analysis

8-K filing: Stock split 1-for-8 | Outstanding: 79,442,633 → 9,930,329

10-Q filing | 79.4M shares outstanding

10-Q filing | 42.0M shares outstanding

10-Q filing | 41.9M shares outstanding

10-Q filing | 39.0M shares outstanding

10-K filing | 39.0M shares outstanding

10-Q filing | 37.9M shares outstanding

10-Q filing | 37.9M shares outstanding

10-Q filing | 37.8M shares outstanding

10-K filing | 37.8M shares outstanding

S-3 filing: The company is filing an S-3 to offer and sell up to $200,000,000 in any combination of common stock, preferred stock, debt securities, or warrants from time to time.

10-Q filing | 37.2M shares outstanding

S-3 filing: This prospectus relates to the offer and sale by us of 32,516,267 shares of our common stock, par value $0.001 per share, that are issuable upon the exercise of warrants.

10-Q filing | 37.2M shares outstanding

10-Q filing | 36.5M shares outstanding

10-K filing | 33.3M shares outstanding

10-Q filing | 32.7M shares outstanding

10-Q filing | 32.7M shares outstanding

10-Q filing | 32.1M shares outstanding

8-K filing: SCYNEXIS, Inc. entered into an Equity Underwriting Agreement for the offering, issuance and sale of 3,333,333 shares of common stock, pre-funded warrants to purchase 11,666,667 shares of common stock, and warrants to purchase up to 15,000,000 shares of common stock, with the offering expected to close on or about April 26, 2022. ($41.9M proceeds)

10-K filing | 28.9M shares outstanding

10-Q filing | 24.0M shares outstanding

S-3 filing: SCYNEXIS, Inc. is filing this registration statement as its Registration Statement on Form S-3 (File No. 333-227167) will be expiring on September 14, 2021 and is registering the offering and sale of shares of common stock previously offered but not yet sold pursuant to the Prior Registration Statement.

10-Q filing | 23.2M shares outstanding

10-Q filing | 20.6M shares outstanding

10-K filing | 20.6M shares outstanding

S-3 filing: The filing is an S-3 registration statement for the potential offering of common stock, preferred stock, debt securities, and warrants up to an aggregate amount of $200,000,000.

8-K filing: SCYNEXIS, Inc. entered into an Equity Underwriting Agreement for the offering, issuance and sale of 8,340,000 shares of common stock, pre-funded warrants to purchase 5,260,000 shares of common stock, and warrants to purchase up to an aggregate of 13,600,000 shares of common stock, with the offering expected to close on or about December 21, 2020. ($79.5M proceeds)

10-Q filing | 10.6M shares outstanding

S-3 filing: The filing is for a $50,000,000 at-the-market offering of common stock through Cantor Fitzgerald & Co. and Ladenburg Thalmann & Co. Inc. as sales agents.

10-Q filing | 10.6M shares outstanding

8-K filing: Stock split 1-for-10 | Outstanding: 98,587,061 → 9,858,706

10-Q filing | 98.6M shares outstanding

S-3 filing: This S-3 filing registers 19,386,000 shares of common stock issuable pursuant to convertible senior notes for sale by the selling stockholder.

8-K filing: SCYNEXIS issued and sold $10.0 million aggregate principal amount of its 6.0% Senior Convertible Notes due 2026 to Puissance Life Science Opportunities Fund VI on April 9, 2020, convertible into common stock at an initial conversion price of $0.90 per share, subject to a share cap of 19,386,000 shares unless stockholder approval is obtained. ($10.0M proceeds)

10-K filing | 97.4M shares outstanding